20.500.12556/DiRROS-14720 Heterogeneous response of airway eosinophilia to anti-IL-5 biologics in severe asthma patients Many questions concerning responders (R) and nonresponders (NR) in severe eosinophilic asthma (SEA) after blocking the IL-5 (interleukin 5) pathway are still not clear, especially regarding the early parameters of response to biologics in personalized treatment strategies. We evaluated 17 SEA patients treated with anti-IL-5 biologics (16 patients mepolizumab, one patient benralizumab) before the introduction of biologics, and at a week 16 follow-up. Clinical, cellular and immunological parameters in peripheral blood were measured in R and NR. Sputum induction with the measurement of cellular and immunological parameters was performed at 16 weeks only. There were 12 R and 5 NR to biologics. After 16 weeks, there was a significant improvement in percentages of FEV1 (p = 0.001), and asthma control test (ACT) (p = 0.001) in the R group, but not in NR. After 16 weeks, the eosinophils in induced sputum were 27.0% in NR and 4.5% in R (p = 0.05), with no difference in IL-5 concentrations (p = 0.743). Peripheral eosinophilia decreased significantly in NR (p = 0.032) and R (p = 0.002). In patients with SEA on anti-IL-5 therapy, there was a marked difference in airway eosinophilic inflammation between R and NR already at 16 weeks, after anti-IL-5 introduction. težka astma anti-IL-5 biološka zdravila eozinofilija dihalne poti sputum true false true MDPI Angleški jezik Ni določen © 2022 by the authors Neznano 2022-01-13 10:49:52 2022-01-13 10:49:52 2022-08-20 03:37:25 0000-00-00 00:00:00 2022 0 Švica 0 Nasl. z nasl. zaslona; Maruša Kopač Šokić in Matija Rijavec sta enakovredna prva avtorja; Opis z dne 11. 1. 2022; Članek št. 70; str. 1-12 iss. 1 Vol. 12 2022 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.2 2075-4426 10.3390/jpm12010070 92821507 RAZ_Kopac_Marusa_i2022.pdf RAZ_Kopac_Marusa_i2022.pdf 1 2D1E19734BDB21EEC30F6F74C9643323 8e858b4d8ebd025ce63824e5dfdbe1fe40d25402b9eec57f950bd028c0794e1c cfc7062e-17b6-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=18920 https://www.mdpi.com/2075-4426/12/1/70 1 https://dirros.openscience.si/Dokument.php?lang=slv&id=18919 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0